TherapeuticsMD (TXMD) Cantor Healthcare Conference - Slideshow

Imvexxy - Imvexxy's launch strategy is showing strong results and is on track[9] - Imvexxy's market share reached 9% by month 14[13] - Imvexxy patients average 38 fills per year, higher than vaginal creams (15 fills/year) and vaginal tablets (35 fills/year)[18] Bijuva - Bijuva launched in April 2019, targeting the separate bio-identical Estrogen & Progesterone pills segment[40] - As of August 2019, Bijuva had approximately 14,200 total paid scripts dispensed to patients and approximately 5,300 total paid scripts in August alone[45] - As of August 2019, Bijuva had approximately 6,800 total patients and approximately 3,000 total prescribers[45] Annovera - Annovera's test and learn market introduction has begun, with a full launch expected in Q1 2020[67] - The unique commercial payer environment for Annovera provides the expectation for initial net revenue of at least $1,100 per unit[67] - 44% commercial coverage was achieved in under one month of Annovera being available in the channel[67] Market Overview - The VVA (Vulvar and Vaginal Atrophy) market exceeds $17 billion in gross revenue annually[29, 30]